Yonsa Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9889144 SUN PHARM Abiraterone acetate formulation and methods of use
Mar, 2034

(9 years from now)

US10292990 SUN PHARM Abiraterone steroid formulation
May, 2034

(9 years from now)

Yonsa is a drug owned by Sun Pharmaceutical Industries Ltd. It is used for treating prostate cancer in combination with methylprednisolone. Yonsa uses Abiraterone Acetate as an active ingredient. Yonsa was launched by Sun Pharm in 2018. It is is available in tablet form for oral use. Its generic launch date based on the expiry of its last outstanding patent is estimated to be May 20, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ABIRATERONE ACETATE ingredient

Market Authorisation Date: 22 May, 2018

Treatment: Use in combination with methylprednisolone for the treatment of patients with prostate cancer

Dosage: TABLET

How can I launch a generic of YONSA before it's drug patent expiration?
More Information on Dosage

YONSA family patents

Family Patents